FF and PMH are funded by Kings College London. We would like to thank Dr Jon Mitchell for his technical assistance in constructing the mRNA expression vector and Dr Helena Daniels for her technical assistance with the T cell proliferation assays. References 1. Wang RF, Rosenberg SA: Human tumor antigens for cancer vaccine development. Immunol Rev 1999, 170:85–100.PubMedCrossRef 2. Parkin DM, Bray
F, Ferlay J, buy Duvelisib Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74–108.PubMedCrossRef 3. O’Beirne JP, Harrison PM: The role of the immune system in the control of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2004, 16:1257–1260.PubMedCrossRef 4. Gaffey MJ,
Joyce JP, Carlson GS, Esteban JM: Spontaneous regression of hepatocellular carcinoma. Cancer 1990, 65:2779–2783.PubMedCrossRef 5. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW, Tang ZY: Intratumoral balance of regulatory and cytotoxic T cells CH5183284 order is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007, 25:2586–2593.PubMedCrossRef 6. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Teicoplanin Kakizoe T: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000, 356:802–807.PubMedCrossRef 7. Knutson KL, Wagner W, Disis ML: Adoptive T cell therapy of solid cancers. Cancer Immunol Immunother 2006, 55:96–103.PubMedCrossRef 8. Iglesias BV, Centeno G, Pascuccelli H, Ward F, Peters MG, Filmus J, Puricelli L, de
Kier Joffe EB: Expression pattern of glypican-3 (GPC3) during human embryonic and fetal development. Histol Histopathol 2008, 23:1333–1340.PubMed 9. Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J: Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003, 125:89–97.PubMedCrossRef 10. Shirakawa H, Suzuki H, Shimomura M, Kojima M, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kobayashi N, ITF2357 concentration Kinoshita T, Nakatsura T: Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci 2009, 100:1403–1407.PubMedCrossRef 11. Motomura Y, Ikuta Y, Kuronuma T, Komori H, Ito M, Tsuchihara M, Tsunoda Y, Shirakawa H, Baba H, Nishimura Y, Kinoshita T, Nakatsura T: HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice. Int J Oncol 2008, 32:985–990.PubMed 12.